We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE icon
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Miscellaneous 1.72%
3 Financials 1.69%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ATRC icon
51
AtriCure
ATRC
$2.9B
$9.18M 0.37%
+300,000
New +$9.35M
2018 Q4
0 quarters
CMRX icon
52
DELISTED
Chimerix, Inc.
CMRX
$9.16M 0.37%
3,564,950
-26,100
-0.7% -$87.4K
2016 Q2
10 quarters
AXNX icon
53
DELISTED
Axonics, Inc. Common Stock
AXNX
$9.07M 0.36%
+600,000
New +$8.93M
2018 Q4
0 quarters
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.88M 0.28%
+167,600
New +$6.28M
2018 Q4
0 quarters
KRYS icon
55
Krystal Biotech
KRYS
$9.85B
$6.75M 0.27%
+325,000
New +$6.8M
2018 Q4
0 quarters
ODT
56
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.43M 0.26%
456,951
-148,349
-25% -$2.31M
2017 Q4
4 quarters
NVTA
57
DELISTED
Invitae Corporation
NVTA
$5.81M 0.23%
525,375
– –
2015 Q1
15 quarters
ONC icon
58
BeOne Medicines Ltd
ONC
$42.1B
$5.67M 0.23%
40,400
+100
+0.2% +$13.3K
2018 Q1
3 quarters
ESTA icon
59
Establishment Labs
ESTA
$1.83B
$3.9M 0.16%
142,167
-7,833
-5% -$191K
2018 Q3
1 quarter
OVID icon
60
Ovid Therapeutics
OVID
$439M
$1.78M 0.07%
737,550
+7,400
+1% +$33.8K
2017 Q2
6 quarters
ARVN icon
61
Arvinas
ARVN
$468M
$1.75M 0.07%
136,300
– –
2018 Q3
1 quarter
JNCE
62
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$864K 0.03%
256,473
-168,942
-40% -$789K
2017 Q1
7 quarters
ELGX
63
DELISTED
Endologix Inc
ELGX
$575K 0.02%
80,048
-998
-1% -$11.1K
2015 Q4
12 quarters
LHCG
64
DELISTED
LHC Group LLC
LHCG
$394K 0.02%
4,200
-213,280
-98% -$20.4M
2018 Q3
1 quarter
MYOK
65
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$387K 0.02%
7,930
+760
+11% +$41.8K
2018 Q2
2 quarters
RGEN icon
66
Repligen
RGEN
$11.7B
$317K 0.01%
6,020
-13,980
-70% -$820K
2018 Q3
1 quarter
VCEL icon
67
Vericel Corp
VCEL
$2.11B
$291K 0.01%
16,720
-3,280
-16% -$49.1K
2018 Q2
2 quarters
SAGE icon
68
DELISTED
Sage Therapeutics
SAGE
$283K 0.01%
2,950
+780
+36% +$89.3K
2018 Q2
2 quarters
GWPH
69
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$275K 0.01%
+2,820
New +$370K
2018 Q4
0 quarters
IRTC icon
70
iRhythm Holdings
IRTC
$3.54B
$272K 0.01%
+3,910
New +$296K
2018 Q4
0 quarters
FLXN icon
71
DELISTED
Flexion Therapeutics, Inc.
FLXN
$150K 0.01%
13,260
– –
2018 Q1
3 quarters
VKTX icon
72
Viking Therapeutics
VKTX
$3.4B
$124K 0.01%
16,260
-13,740
-46% -$164K
2018 Q3
1 quarter
ACRS icon
73
Aclaris Therapeutics
ACRS
$512M
$84K ﹤0.01%
11,320
– –
2016 Q4
8 quarters
ADVM icon
74
DELISTED
Adverum Biotechnologies
ADVM
$70K ﹤0.01%
2,224
– –
2016 Q2
10 quarters
SBBP
75
DELISTED
Strongbridge Biopharma plc.
SBBP
$56K ﹤0.01%
+12,500
New +$61K
2018 Q4
0 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.